The recent prospective study of the West Japan Oncology Group 8114LTR (WJOG8114LTR) evaluated the clinical significance of monitoring ctDNA in 57 patients with advanced lung adenocarcinoma harboring EGFR mutations during afatinib treatment. The gene discussed is EGFR; the disease is lung adenocarcinoma.